Skip to main content

Inovio Pharma(INO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Inovio Pharma

660 W. GERMANTOWN PIKE SUITE 110
PLYMOUTH MEETING PA 19462 USA
P: 267-440-4200
F: 267-440-4242
http://www.inovio.com

Profile

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Key Executives

NameTitle
Peter D. KiesCFO/Chief Accounting Officer
Laurent HumeauChief Scientific Officer
Jacqueline E. SheaCEO/Director/President
Michael John SumnerChief Medical Officer